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the course of the disease. Combinations of
cyclophosphamide, plasmapheresis, and steroids may
also have short-term beneficial effects in MS.1O.21
Unfortunately immunosuppressive drugs, particularly
alkylating agents, have a close therapeutic/toxic ratio
and a wide range of side-effects.22 Although long-term
risks of malignant disorders in patients with non-
neoplastic disease treated with immunosuppressive
drugs are not precisely defined, alkylating agents such as
cyclophosphamide have been associated with a higher
than expected incidence of malignant disorders of the
blood.19 Even less is known about long-term risks of
immunosuppressive drugs in MS. However, in one MS
study, a 2.5-fold increased risk of cancer was found in
131 patients treated with azathioprine for a mean of 6
years and malignant disorders occurred in almost 10%
of the subgroup of MS patients followed 5 years or
longer.23 TLI seems not to be associated with a high risk
of neoplasia and generally produces few serious side-
effects in long-term follow-up.s>6
TLI and immunosuppressive drugs in MS each have
another theoretical advantage and disadvantage. By
sparing the brain, TLI cannot damage its
oligodendrogliocytes, thereby allowing the possibility of
remyelination, whereas immunosuppressive drugs
which cross a normal or damaged blood-brain barrier
might injure the oligodendrogliocytes and inhibit
remyelination. On the other hand, TLI does not
eliminate immunocompetent cells in the brain; if MS is
an autoimmune disease, these cells could continue to
cause immune-mediated tissue injury for their lifetime
in the CNS.
TLI therefore appears to be a promising new therapy
for the treatment of patients with chronic progressive
MS. However, amplification of our results is needed
before the overall efficacy of TLI in MS can be judged
and the subgroups of patients who might most benefit
identified. In the mean time, TLI should be considered
an experimental therapy in MS patients and its use in
this disorder restricted to MS study groups.
Addendum
Subsequent to completion of this study, 1 severely
disabled MS patient, 3 years after TLI, died from a
flu-like syndrome complicated by staphylococcal
pneumonia, obstruction of her endotracheal tube, and
cardiorespiratory arrest.
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Summary The density and affinity of beta-2-
adrenoceptors on mononuclear cells
from peripheral blood were studied in fifteen patients
with cirrhosis of different severity and in thirteen
controls. There was no significant difference between
cirrhotic patients and controls in density or affinity of
beta-2 binding sites. Within the cirrhotic group,
however, the number of binding sites per cell was
significantly lower in patients with severe ascites than in
patients with mild to moderate or no ascites. This
down-regulation of beta-adrenoceptors could influence
the haemodynamic response to beta-blockers.
Introduction
LEBREC and colleagues1.2 found that the non-selective
beta-adrenoceptor blocker propranolol reduced the
frequency of gastrointestinal rebleeding in patients with
cirrhosis and oesophageal varices, but this finding was
not confirmed by Burroughs et awl. This discrepancy
might be due to differences in the severity of cirrhosis in
the selected patients, since the stage of liver disease
influences the haemodynamic effects of propranolol. 4
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Thus, the severity of cirrhosis might affect the density or
affinity of beta-adrenoceptors. We have studied beta-
adrenoceptor status in patients with cirrhosis of
different severity.
Subjects and Methods
We compared fifteen cirrhotic patients, ten men and five
women, aged 41-76 years (median 56 years), three grade A, nine
grade B, three grade C by a modified Child classification, 5,6 and
thirteen controls, seven men and six women, aged 36-81 years
(median 55 years). No subject was receiving drugs for treatment
of the cardiovascular system. Most of the patients were taking
antacids, diuretics (spironolactone 0-400 mg daily, or
frusemide 0-80 mg daily), vitamin K, and lactulose. The
severity of ascites was determined by physical examination and
ultrasound the day before the receptor status determinations.
Clinical and laboratory data were collected independently by
different physicians and treated separately until statistical
analysis.
Mononuclear cells were separated from samples of peripheral
blood taken in the morning by means of ’Ficoll-Hypaque’
(Pharmacia, Heidelberg).7 There is evidence that the beta-2-
adrenoceptors on these lymphocytes and monocytes represent
those in other organs,8,9 and these readily available cells are
commonly used for beta-2-adrenoceptor investigations.1o,1
Specific binding of iodine-125-labelled cyanopindolol (2100
Ci/mmol, Amersham) was measured by incubating 1 ml cell
suspension (5 x 105 cells) at 37&deg;C for 90 min with or without 0-1 1
jJ.mol/1 timolol. Incubation was ended by centrifugation at
18 000 g. At least eight different ligand concentrations were
used for determining the receptor status of each ’subject.
Density of binding sites (Bmax) and apparent equilibrium
dissociation constant (Kd), as an indicator of affinity were
calculated according to Scatchard. 12 Statistical significance was
determined by the two-tailed Mann-Whitney test; a p value less
than 0-05 was considered significant. Correlations were
analysed by polynomial regression. ,
Results
There were no significant differences between the
cirrhotic patients and the controls in Bmax (509-1958,
median 1035, vs 595-2120, median 1034, binding sites
per cell) or Kd (1-8-53, median 2-7 x 10-12 mol/l vs
1-6-8-6, median 4-1 x 10-12 mol/1). Neither age nor sex
was correlated with Bmaxor Kd in either group. The heart
rate in cirrhotic patients (76-100, median 84 beats-/min)
was significantly higher than that in controls (60-88,
median 68 beats/min). This elevation, possibly
indicating increased adrenergic activity of the beta-
1-adrenoceptors, was not correlated with the density of
beta-2-adrenoceptors. Furthermore, in the cirrhotic
patients no correlation was found between beta-receptor
status and the dosage of various drugs, particularly the
extent of diuretic treatment, or several indicators of the
severity of liver disease, such as serum bilirubin, serum
albumin, prothrombin time, and Child-Pugh score.
There was no significant correlation between Bmax and
plasma potassium in patient or control group. However,
there was a significant (p<0.01) negative correlation
(r = &mdash; 0-73) between the density of binding sites and the
grade of ascites defined by physical examination and
ultrasound (fig 1). The reduced receptor density and
unchanged affinity in a representative cirrhotic patient
with severe ascites are shown in fig 2.
Discussion
In view of the high plasma catecholamine levels
reported in decompensated cirrhosis,13,14 the reduction
in beta-2-adrenoceptors in cirrhotic patients with severe
Fig 1-Density of beta-2-adrenoceptors in cirrhotic patients
with no ascites (grade 0), mild to moderate (grade 1) ascites, or
severe (grade 2) ascites.
Fig 2-Represeiitative Scatchard plots of one patient with no
ascites and one patient with severe ascites.
ascites can be interpreted as down-regulation. Down-
regulation of beta-adrenoceptor density can be assumed
to affect the haemodynamic response to beta-blocking
drugs. This finding is particularly interesting, since
selective beta-2 blockade is being recommended as
pharmacological treatment in portal hypertension. 15-17
Because of the pronounced differences in receptor
density between individuals, the determination of beta-
adrenoceptor status might prove useful in selecting the
appropriate dose18 of beta-blocking agents. Finally, our
findings could offer an explanation for the discrepant
results of propranolol treatment for prevention of
recurrent gastrointestinal bleeding;2,3 patients with
severe cirrhosis and severe ascites, included in
Burroughs’3 but not in Lebrec’s2 study, may have shown
less response to propranolol owing to down-regulation
of beta-2-adrenoceptors. -
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